Proteomics International Laboratories Ltd
ASX:PIQ

Watchlist Manager
Proteomics International Laboratories Ltd Logo
Proteomics International Laboratories Ltd
ASX:PIQ
Watchlist
Price: 0.675 AUD 2.27% Market Closed
Market Cap: 88.4m AUD
Have any thoughts about
Proteomics International Laboratories Ltd?
Write Note

Proteomics International Laboratories Ltd
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Proteomics International Laboratories Ltd
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Proteomics International Laboratories Ltd
ASX:PIQ
Total Equity
AU$9.4m
CAGR 3-Years
7%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Anteotech Ltd
ASX:ADO
Total Equity
AU$5.3m
CAGR 3-Years
-37%
CAGR 5-Years
5%
CAGR 10-Years
-3%
T
Trajan Group Holdings Ltd
ASX:TRJ
Total Equity
AU$102.8m
CAGR 3-Years
16%
CAGR 5-Years
45%
CAGR 10-Years
N/A
Cryosite Ltd
ASX:CTE
Total Equity
AU$1.4m
CAGR 3-Years
57%
CAGR 5-Years
N/A
CAGR 10-Years
-13%
Genetic Signatures Ltd
ASX:GSS
Total Equity
AU$61.1m
CAGR 3-Years
7%
CAGR 5-Years
42%
CAGR 10-Years
N/A
E
EZZ Life Science Holdings Ltd
ASX:EZZ
Total Equity
AU$21.3m
CAGR 3-Years
28%
CAGR 5-Years
92%
CAGR 10-Years
N/A
No Stocks Found

Proteomics International Laboratories Ltd
Glance View

Market Cap
88.4m AUD
Industry
Life Sciences Tools & Services

Proteomics International Laboratories Ltd. is a medical technology company which operates at the forefront of predictive diagnostics and bio-analytical services. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2015-04-16. The firm is engaged in predictive diagnostics and bio-analytical services. The firm specializes in proteomics, the study of the structure and function of proteins. The firm focuses on developing and commercializing diagnostic tests for chronic diseases. The firm operates in three business units unified by a technology platform: PromarkerD, Diagnostics and Analytical Services. PromarkerD is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes. Diagnostics includes Promarker platform, used to discover, verify, and analytically validate the panel of protein biomarkers for diabetic kidney disease. Analytical Services includes proteomics-based technology platform, used to test, and validate the protein composition of a wide and varied range of products.

PIQ Intrinsic Value
0.528 AUD
Overvaluation 22%
Intrinsic Value
Price

See Also

What is Proteomics International Laboratories Ltd's Total Equity?
Total Equity
9.4m AUD

Based on the financial report for Jun 30, 2024, Proteomics International Laboratories Ltd's Total Equity amounts to 9.4m AUD.

What is Proteomics International Laboratories Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
26%

Over the last year, the Total Equity growth was 12%. The average annual Total Equity growth rates for Proteomics International Laboratories Ltd have been 7% over the past three years , 26% over the past five years .

Back to Top